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Abstract
Background
Visceral Leishmaniasis (VL), a severe parasitic disease, could be fatal if diagnosis and
treatment is delayed. Post kala-azar dermal leishmaniasis (PKDL), a skin related outcome,
is a potential reservoir for the spread of VL. Diagnostic tests available for VL such as tissue
aspiration are invasive and painful although they are capable of evaluating the treatment
response. Serological tests although less invasive than tissue aspiration are incompetent
to assess cure. Parasitological examination of slit-skin smear along with the clinical symp-
toms is routinely used for diagnosis of PKDL. Therefore, a noninvasive test with acceptable
sensitivity and competency, additionally, to decide cure would be an asset in disease man-
agement and control.
Methodology/principal findings
We describe here, the development of antibody-capture ELISA and field adaptable dipstick
test as noninvasive diagnostic tools for VL and PKDL and as a test of cure in VL treatment.
Sensitivity and specificity of urine-ELISA were 97.94% (95/97) and 100% (75/75) respec-
tively, for VL. Importantly, dipstick test demonstrated 100% sensitivity (97/97) and specific-
ity (75/75) in VL diagnosis. Degree of agreement of the two methods with tissue aspiration
was 98.83% (κ = 0.97) and 100% (κ = 1), for ELISA and dipstick test, respectively. Both the
tests had 100% positivity for PKDL (14/14) cases. ELISA and dipstick test illustrated
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treatment efficacy in about 90% (16/18) VL cases when eventually turned negative after six
months of treatment.
Conclusions/significance
ELISA and dipstick test found immensely effective for diagnosis of VL and PKDL through
urine samples thus, may substitute the existing invasive diagnostics. Utility of these tests
as indirect methods of monitoring parasite clearance can define infected versus cured.
Urine-based dipstick test is simple, sensitive and above all noninvasive method that may
help not only in active VL case detection but also to ascertain treatment response. It can
therefore, be deployed widely for interventions in disease management of VL particularly in
poor resource outskirts.
Author Summary
Visceral leishmaniasis (VL), one of the most prevalent parasitic diseases in the developing
world causes serious health concerns. Post kala-azar dermal leishmaniasis (PKDL) is a
skin disease which occurs after treatment as a sequel to VL. Parasitological diagnosis
involves invasive tissue aspiration which is tedious and painful. Commercially available
immunochromatographic rapid diagnostic test such as rK39-RDT is used for field diagno-
sis of VL, detects antibodies in serum samples. Urine sample is however, much easier in
collection, storage and handling than serum and would be a better alternative where col-
lection of tissue aspirate or blood is impractical. In this study, we have developed and eval-
uated the performance of two urine-baseddiagnostic assays, ELISA and dipstick test, and
compared the results with serological rK39-RDT. Our study shows the capability of urine-
based tests in detecting anti-Leishmania antibodies effectively for both VL and PKDL
diagnosis. The ability of dipstick test to demonstrate negative results after six months in
90% of the VL cases after treatment could be useful as a test of clinical cure. Urine-based
tests can therefore replace the need for invasive practices and ensure better diagnosis
under filed settings.
Introduction
Visceral Leishmaniasis (VL) is a vector-borne fatal infectious disease disseminated in 88 coun-
tries of the world, particularly in remote areas of India, Bangladesh, Sudan, Brazil, Ethiopia and
South Sudan where 90% of the cases occur [1]. Around 200 to 400 thousands of new VL cases
are reported every year globally [2]. Definitive diagnosis is important in the early phase of
infection as drugs available for this disease have severe side effects [3]. Microscopic visualisa-
tion of spleen or bonemarrow aspirates considered as a gold standard test for the confirmation
of VL is conventionally used wherever feasible, although risky, painful and an invasive practice
demanding expertise [4]. A molecular diagnosis like polymerase chain reaction (PCR) is con-
strained to research labs and tertiary hospitals only [5]. The presence of high levels of antibod-
ies in the sera of VL patients was exploited for serological diagnosis using enzyme-linked
immune sorbent assay (ELISA), direct agglutination test (DAT) and immunochromatographic
rapid diagnostic test (RDT). The fact that ELISA and DAT are time taking, sophisticated and
labour intensive, limits these methods for routine diagnosis in the majority of the VL endemic
Urine-Based Diagnosis of Visceral Leishmaniasis and PKDL
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areas [6]. Antigen rk39 (39 amino acid kinesin-related protein) based RDTs are the most com-
monly used rapid test for sero-diagnosis of VL, especially in the Indian subcontinent where it
gave sensitivity and specificity estimates of 97% and 90.2%, respectively [7]. However, their
diagnostic performance varies frommoderate in Latin America to even low in East African
region [8]. Other than rK39, many newer recombinant antigens such as rKE16, rK28, and
rKLO8 have been developed in the last decade for serological diagnosis [9–11]. Leishmania-
specific antibodies remain within the infected blood for years after treatment. Thus serum-
based antibody detection tests cannot serve as a test of cure [12].
To overcome the shortcomings of serum-baseddiagnostic tests several studies have been
conducted to find a noninvasive biological source for VL diagnosis such as use of saliva and
urine samples instead of serum [13]. For example, PCR have been found 88%-96.8% sensitive
when conducted with DNA extracted from urine samples [14–16]. Saliva as diagnostic sample
has been reported with 58.6%-82.5% and 83.3% sensitivity in rK39-RDTs and ELISA, respec-
tively [17,18]. rK39-RDTs for sero-diagnosticswere also tested with urine samples in several
studies and found sensitivities and specificities of 96.40% and 66.2–100%, respectively [19].
Urine-based latex agglutination test (KAtex) for detecting leishmanial antigen in urine is ham-
pered by low sensitivity (47%-95%) and obligation to boil the samples to increase the test speci-
ficity [20]. Apart from KAtex, several urine-based antigen detection assays have been reported
in recent years with varying performances [21,22]. Very few antibody capture ELISA have been
conducted for diagnosis of VL through urine samples but not in the Indian region [23,24].
Post kala-azar dermal leishmaniasis (PKDL) is a skin disease caused by the same Leish-
mania donovani parasite responsible for VL [25]. In VL endemic areas serologywith clinical
presentation such as macules, papules, plaques or nodules, suggest probable PKDL. However,
confirmation of PKDL relies on parasitological examination of slit-skin smear (SSS) or biopsy
[26].
In the present study, we aimed to develop and evaluate urine-basedELISA and dipstick test
as noninvasive diagnostic tools and compared with serum-basedcommercially available
rK39-RDT using parasitologically confirmedVL cases from geographically important endemic
areas of India. We have also assessed the performance of ELISA and dipstick test for PKDL
diagnosis through urine samples. To determine the presence of VL antibodies of urine in
response to therapy, this study was extended to comprise the evaluation of urine-basedELISA
and dipstick test after six months of treatment. Our results confirmed the potential of urine
samples in ELISA and dipstick test for the noninvasive diagnosis of VL and PKDL and as a test
of clinical cure for human VL.
Methods
Sample collection
A total of 186 participants were enrolled in the School of Tropical Medicine (STM), Kolkata,
RajendraMemorial Research Institute of Medical Sciences (RMRIMS), Patna, Shri Krishna
Medical College and Hospital (SKMCH), Muzaffarpur and Indian Institute of Chemical Biol-
ogy (IICB), Kolkata duringMarch 2011 to July 2016. Urine samples of 97 parasitologically
proven and rK39-RDT (InBios Int. Inc., USA) tested VL cases were obtained before the treat-
ment started. Out of 97 VL samples, 18 were acquired for longitudinal study at different time
points, before treatment began (day 0), when the treatment completed (day 30), and after six
months since the first sample collected (day>180). Samples were also collected from 75 control
subjects including 25 non-endemic healthy controls (NEHC) from IICB, 25 endemic healthy
controls (EHC) from RMRIMS and STM and 25 symptomatically similar diseases other than
VL (OD) from STM. Fourteen urine samples which were confirmed by skin biopsy or slit-skin
Urine-Based Diagnosis of Visceral Leishmaniasis and PKDL
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smear were collected from PKDL patients. Immediately after collection of urine, sodium azide
(NaN3) was added to each sample at a final concentration of 0.1% as a preservative. The sam-
ples were stored at 4°C refrigeration until use.
Ethics statement
This study was approved by the Ethical Committee of Indian Institute of Chemical Biology,
Kolkata and by the respective hospitals. Written informed consent in their local languages was
taken from the participants or parents, if not adult prior to the study. The reason of collection
and storage of urine samples for evaluation of newly developed immunoassays was clearly
mentioned in the consent form.
ELISA
L. donovani strain AG83 (ATCC PRA-413) parasite was cultured according to the standard
protocol [27]. Recombinant proteins of strain AG83 namely, rGP63 (a 63 kDa recombinant
glycoprotein) and rCPA (a recombinant cysteine protease) were purified from its clones
[28,29]. Soluble leishmanial antigens (SLA) extracted from L. donovani were prepared by the
following [30]. Leishmania promastigote membrane antigen (LAg) was extracted as described
[31]. Antibody capture ELISA was performed using 96-well flat bottom ELISA plates (Nunc
Maxisorp, Denmark). Briefly, 1 μg/well of LAg in phosphate buffer was coated, and plates were
kept overnight at 4°C, afterwards blocked with 1% of bovine serum albumin (BSA) (Sigma,
USA) in phosphate buffer saline (PBS) for 2 h at 37°C. Subsequently, 1:10 dilution of urine
samples followed by 1:4000 diluted HRP-conjugated anti-human IgG (Bangalore GeNei, India)
were applied and incubated at 37°C for 1 h. Plates were washed between each step with PBS
containing Tween-20. Finally, 5 mg o-phenylenediamine dihydrochloride (OPD, Sigma, USA)
and 0.05% H2O2 (Merck, Germany) in 10 ml phosphate-citrate buffer were added for 15 min
at room temperature (RT) and the optical densities were read at 492 nm.
Dot blot assay
Nitrocellulosemembrane (Hybond 0.45 μm, GE Healthcare, UK) was cut in the form of rectan-
gular strips and soaked in 25 mM Tris-HCl buffer (pH 7.6). In a semi-dried condition, 1.5 μg
of LAg in 2 μl Tris-HCl buffer were coated in the form of a dot. After complete drying, free
areas of the strips were blocked with 5% of BSA + 0.1% Tween-20 and 0.01% NaN3 in 100 mM
Tris Buffer Saline (TBS) and incubated at 4°C overnight. Next day, strips were washed thrice
with 100 mMTBS and 0.05% Tween-20 (TBS-T) followed by drying at RT. Subsequently,
urine samples at 1:5 dilution in TBS-T were incubated with the strips for 30 min at RT. After
two washes in TBS-T, strips were incubated with 1:2000 diluted peroxidase-conjugated goat
anti-human IgG for 30 min at RT. Following, two washes in TBS-T and a final wash in 100
mMTBS (without Tween-20), strips were incubated for 5 min in a freshly prepared substrate
solution having 0.05% of 3, 3’-diaminobenzidine tetrahydrochloride (DAB, Sigma, USA) con-
taining 0.05% of H2O2 in 100 mM TBS. The reaction was stopped by dipping the strips in dis-
tilled water for 2 min. Dark brown colour spot depicted anti-Leishmania reactivity of urine
samples.
Dipstick development and assay
Nitrocellulosemembrane-based dipstick was prepared to have a test and a control line for
visual detection of the disease. In brief, 1.5 μg of LAg/dipstick at the test line and 1: 20 dilution
of rabbit anti-human IgG at the control line were bound to the membrane and blocked with
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5% BSA at 4°C overnight. Next day after drying, the membrane was adhered to a plastic sheet
and stored at RT until the test. Like dot blot assay the dipstick test comprises incubation with
urine sample followed by enzyme-conjugated anti-human IgG and then substrate chromogen
including washing in each step. Dark brown coloured bands both at the test and control line
show VL positivity and a single band at the control line infers VL negativity.
Statistics
Statistical analyses were performedwith Graph Pad Prism version 5.0. Two-tailed, Mann-
WhitneyU test was used for comparison of ELISA values of different groups and considered
statistically significant if the P values<0.05. A receiver-operator characteristic (ROC) curve for
ELISA was constructed to determine the cut-off value with 95% confidence intervals (CI) that
discriminate betweenVL-positive and -negative urine samples. To assess the overall perfor-
mance of the test sensitivity and specificity were calculated and diagnostic accuracywas estab-
lished by area under the curve (AUC) where AUC = 1 indicates an accurate test. Kappa values
(0.8–1, perfect agreement) were estimated to find the degree of agreement for urine-based
ELISA and dipstick test with the reference test of tissue aspiration.
Results
Antibody capture ELISA for diagnosis of VL and PKDL
To assess Leishmania proteins as potential noninvasive diagnostic candidate antibody capture
ELISA was performed as a proof of principle experiment with four leishmanial antigens,
rGP63, rCPA, SLA and LAg. LAg showed better recognition of IgG antibodies in VL urine with
high specificity compared to other tested antigens (Fig 1). Reactivity of LAg was also investi-
gated against other antibody isotypes, IgA, IgM and IgE present in the urine samples. Presence
of high levels of anti-leishmanial IgG antibodies in VL urine samples than non-VL controls dis-
tinguishes disease condition better over other antibody isotypes (Fig 2). Parameters such as
urine dilution and antigen concentrations were standardised to set optimal ELISA condition
for the diagnosis (S1 and S2 Figs). Finally, all urine samples were examined by ELISA and
results were interpreted to find urine IgG reactivity of each group against LAg (Fig 3). With the
assessment of ROC curve (Fig 4), the test cut-off point, 0.1875 was selected from possible cut-
offs at 95% CI. Urine from VL patients illustrated significantly (P<0.0001) stronger recogni-
tion against LAg with a high degree of specificity. The test showed positivity in 95 of 97 VL
cases, yielding a sensitivity of 97.94% for detection of Leishmania exposure. False negative
results were found for 2 (2.06%) of 97 VL samples. All 14 PKDL samples showed antibody
titres above the cut-off line thus 100% sensitive for urine ELISA. Overall specificity was calcu-
lated using 75 non-VL urine samples of controls and found 100% specificitywithout any false
positives. Anti-LAg antibody titre in VL urine is 27, 12 and 16 times higher than those of
NEHC, EHC and OD, respectively (Fig 3). The AUC obtained for the test was 0.9984, depicting
its potential to discriminate cases with and without the disease and comprises a high degree of
agreement (κ = 0.97) with the gold standard test. Additionally, two VL cases which were parasi-
tologically confirmed but negative to rK39-RDT with serumwere found positive in urine
ELISA, suggesting their better performance in comparison to serum rK39-RDT.
Urine ELISA as a test of cure
To determine the urine antibody levels in response to treatment, we selected paired urine sam-
ples from 18 VL patients at day 0, day 30 and day>180. There is no significant decline in the
titre just after completing the treatment (day 30). Out of 18 urine samples, 16 showed a
Urine-Based Diagnosis of Visceral Leishmaniasis and PKDL
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significant decrease (p<0.0001) in the urine IgG titre only after six months (day> 180) since
the treatment started (Fig 5).
Dot blot assay
Principles of ELISA were adapted in the form of dot blot to develop a nitrocellulosemembrane
based diagnostic test. Dot blot optimisation was performedwith urine samples from different
groups to see the qualitative reactivity of the antigen on the membrane. Antigen concentration
of 1.5 μg/dot, urine dilution of 1:5 and blocking with 5% BSA were optimised for the assay (S3–
S5 Figs). Under these conditions, 10 VL samples and 11 non-VL controls were used in the dot
blot experiment. Urine from confirmedVL cases tested positive, and the non-VL controls were
all negative in the assay as determined by the visual observation (Fig 6). Anti-human IgG was
selected and optimised for the assay as an experimental control which show reactivity with
urine IgG irrespective of their specificity (S6 Fig).
Dipstick assay as a noninvasive diagnostics for VL and PKDL
Dot blot assay was transformed into a field adaptable dipstick format as discussed in Methods
Section for the qualitative detection of total IgG in human urine (S7 Fig). Results of the dipstick
test showed positivity in all VL urine samples, acquiring a sensitivity of 100% (97/97). None of
the urine samples taken from negative controls showed reactivity with the dipstick assay,
resulting in 100% specificity (75/75) of the test. Thus, complete agreement (κ = 1.0) was
Fig 1. Comparison of urine antibody absorbances between VL patients and healthy controls using
four leishmanial antigens. Reactivity of urine (undiluted) from visceral leishmaniasis (VL) patients (n = 5)
and healthy controls (HC) (n = 6) against 2.5 μg/well of leishmanial membrane antigen, LAg; recombinant
glycoprotein 63, rGP63; recombinant cysteine protease A, rCPA and soluble leishmanial antigen, SLA. The
standard error of mean for each group is shown as a solid line.
doi:10.1371/journal.pntd.0005035.g001
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observedbetween the dipstick test and the reference test of tissue aspiration for diagnosis of
VL. In comparison to urine dipstick test, serum-based rK39-RDT showed 95.87% sensitivity
(93/97) and 97.33% specificity (73/75). Two patients with confirmedVL, who were false nega-
tive in our ELISA and with serum rK39-RDT, demonstrated positive dipstick test showing its
aptitude to detect even low antibody titre in urine. All 14 PKDL urine samples tested had posi-
tive results in dipstick assay thus showing 100% sensitivity of the test. The analytical perfor-
mances of dipstick test and ELISA with rK39-RDT are compared in Table 1, and the
representative illustrations of dipstick assay are shown in Fig 7.
Dipstick assay as a test of cure
Evaluation of dipsticks as a test of cure was conducted with 18 paired VL samples at day 0, 30
and>180 after treatment initiation. Samples after one month of therapy (day 30) showed a
decrease in the positivity only in 5 samples as the test line of the dipstick had less intense colour
than the samples using before treatment started (day 0). Out of 18 follow-up samples, 16 were
entirely negative on and after six months of the treatment initiation (day>180). Two samples
remained positive after 6 months of treatment till the data reported (S1 Table).
Discussion
Noninvasive diagnosis of VL has been a challenge for long, and to date no accepted urine-
based rapid test is available. WHO in their 3rd report on neglected tropical diseases in 2015
Fig 2. ELISA to determine relative antibody isotype titres in urine of VL patients and negative
controls. Graph showing comparative optical density values of LAg-specific antibody isotypes; IgG, IgA,
IgM, and IgE present in the urine samples of VL patients (n = 5), healthy controls (HC) (n = 3) and other
diseases (OD) (n = 4) at 492nm.
doi:10.1371/journal.pntd.0005035.g002
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recommended the need of improved diagnostic tests for VL, PKDL and test of cure. We report
here, ELISA and a field adaptable dipstick test which make use of urine samples instead of
serum for diagnosis of VL as well as PKDL diseases. To the best of our knowledge, this is the
first study where a dedicated dipstick test was developed for the detection of leishmanial anti-
gen-specific antibodies from human urine samples and 100% sensitivity, and specificitywas
achieved.We have also reported an ELISA for the first time with urine of PKDL patients,
where it gives 100% sensitivity. Additionally, ELISA and dipstick assay show clearance of the
antibodies from 90% of the urine samples six months after start of treatment. Unlike the blood
stream where antibodies persist for several years after treatment, our data show prospects in
the use of these urine tests for monitoring prognosis following treatment.
Employing LAg as the antigen, the respective sensitivities and specificitieswere found to be
97.94% and 100% in ELISA, and 100% and 100%, in dipstick assay for VL. These findings are
consistent with our earlier reports of diagnostic ability of LAg in detecting serum antibodies
[32]. Single antigens so far were not found very beneficial for diagnosis of VL. LAg is a mixture
of at least ten urine-reactive antigenic polypeptides present in the membrane of the parasite L.
donovani. Reactivity of each polypeptide for urine antibodies gives synergistically better diag-
nostic performance than an antigen alone thus justifying its better diagnostic aptitude over
cloned antigens.
Fig 3. ELISA results with urine samples obtained from VL and PKDL patients, healthy individuals
and other clinical groups. Comparative evaluation of ELISA reactivity of anti-Leishmania antibodies in
urine against LAg at 0.1875 cut-off. The study groups were composed of a panel of VL patients (VL; n = 97),
PKDL patients (n = 14), endemic healthy controls (EHC; n = 25), non-endemic healthy controls (NEHC;
n = 25) and other diseases (OD; n = 25) including malaria (n = 2), viral fever (n = 2), tuberculosis (n = 4),
typhoid (n = 4), liver abscess (n = 3), systemic lupus erythematosus (SLE) (n = 3), sepsis (n = 2), pancreatitis
(n = 1), pneumonia (n = 1), filariasis (n = 1), abdominal pain and loose motion (n = 1), and mouth ulcer (n = 1).
Each sample was tested in duplicate and the mean was taken. Each dot represents mean of a single sample.
doi:10.1371/journal.pntd.0005035.g003
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Urine as diagnostic tool is a thrust in VL research. Several established serologicalmethods
such as ELISA, DAT and RDTs have been tested with urine samples in recent studies. For
example, DAT when conducted with urine samples showed 90.7% and 96.4% sensitivity and
specificity, respectively [33]. Attempts have beenmade in the past few years to identify protein
biomarkers in urine during VL [34,35]. A latex agglutination test such as KAtex has suboptimal
sensitivity in detecting urine antigen in VL diagnosis [20]. A prototype ELISA kit detecting uri-
nary antigen was developed and evaluated in Ethiopia, Sudan, Bangladesh and Brazil. The
overall sensitivities of the kit ranged from 88.4 to 100% with 100% specificity [21]. Leishmania
infantum antigens which are excreted in urine of VL patients were also identified and cloned
[36]. All VL urine samples were reported to be positive in capture ELISA when three leishman-
ial antigen assays were combined [22].
Antibody detection in urine could be beneficial for the noninvasive diagnosis of VL. How-
ever, only few were performed in this area. Islam et al in Bangladesh have investigated urine
IgG using L. donovani crude antigen in ELISA and reported 93.5% sensitivity and 89.3% speci-
ficity [23]. The same group later showed 94% and 99.6% sensitivity and specificity, respectively
with kinesin-related antigen rKRP42 [24]. In these studies VL follow-ups and PKDL patients
were not included and the studies have been only at the ELISA level. Very recently, in Bangla-
desh Ghosh et al have observedonly a marginal drop in the sensitivity and>96% specificity
when urine samples were used and compared with serum by antibody-capture ELISA. In the
study antigen rK28 demonstrated 95.4% sensitivity with urine than 98.9% with serum samples
[37]. We have reported urine-ELISA for the first time with the Indian VL patients and the first
to report for PKDL patients. Here the studies were conducted in three major centres of India
which cover the key endemic areas of VL in this region.
There is no rapid test available for urine-antibody detection from VL and PKDL patients.
Serum-basedrK39-RDTs were tested with urine samples in a study in India and found very
Fig 4. Receiver operator characteristics (ROC) curve for urine ELISA. ROC curve obtained from the
ELISA values for the detection of anti-Leishmania IgG antibodies in urine samples. Cut-off value (0.1875),
sensitivity (97.94%), specificity (100%) and AUC (0.9984) were determined by this curve using GraphPad
Prism software (version 5.0).
doi:10.1371/journal.pntd.0005035.g004
Urine-Based Diagnosis of Visceral Leishmaniasis and PKDL
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0005035 October 14, 2016 9 / 16
low specificity ranging from 66.2% to 77.08% only, thus not considered suitable for VL diagno-
sis in this format [38]. However, similar studies in Bangladesh and two other groups in India
have shown sensitivities and specificities ranging from 95% to 100% and 86.33% to 100%,
respectively [39–41]. Few studies also reported the reactivity of rK39-RDT with PKDL urine
samples though the number of samples used was very few and the results were contradictory.
One of our co-authors Goswami et al [40] showed PKDL positivity with rK39-RDT in six urine
samples whileMohapatra et al [13] reported 3 out of 3 negative PKDL results with urine sam-
ples. We observed100% urine positivity of PKDL cases (14/14) both in ELISA and dipstick
tests. Diagnosis of PKDL is of utmost importance as it may harbour Leishmania parasites in
the skin and provide another reservoir for Leishmania infection.However, PKDL is not a fatal
infection and often evades VL surveillanceprogrammes. Noninvasive diagnosis of PKDL can
help in early identification of PKDL sufferers.
Except the invasive tissue aspiration, present serological diagnostic tests are not good
enough for use as ‘test of cure’ [42]. Decline in antibody response against K39 antigen have
been reported in VL patients but the time to become sero-negative varied [43]. A study showed
antibodies against rK39 antigen remains unaltered in serum after 180 days of treatment. How-
ever, antibodies against rK26 and rK18 demonstrated significant decline in antibody titre of
serum samples after 6 months of treatment [44]. Recently, urine antigen response after VL
therapy has been investigated through ELISA. In the study, Leishmania Antigen Detect ELISA
showed 100% negativity of urine sample at 180 days of treatment [21]. Antibody detection
through serum-based rK39-RDT has been tested with urine of treated VL individuals in two
separate studies. Urine samples of 40 VL follow-ups after 1–3 months and 11 urine samples
Fig 5. Comparison of urine antibody titres of VL patients at different time points of treatment.
Absorbance value of LAg-specific urine antibody titres in VL at day 0, before the treatment started; at day 30,
after drug therapy and at days >180, more than 6 months of treatment started.
doi:10.1371/journal.pntd.0005035.g005
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just after treatment completion were positive with rK39-RDT thus demonstrating its failure as
a test of cure [13,40]. We explored for the first time a significant (16/18) fall of urine antibody
Fig 6. Dot blot assay to identify L. donovani infection. Results showing dot blot assay with VL; 1–10, malaria; 11 and 12, viral fever; 13 and 14,
tuberculosis; 15 and 16, typhoid; 17, endemic healthy control; 18 and 19 and non-endemic healthy control; 20 and 21.
doi:10.1371/journal.pntd.0005035.g006
Table 1. Sensitivity and specificity of urine immunological assays in comparison to serological rK39 test with 95% confidence interval.
Serum Urine
Subjects
(n)
rK39-RDT LAg-ELISA LAg-Dipstick test
Sensitivity N
(%)
Specificity N
(%)
95%
Confidence
Interval
Sensitivity N
(%)
Specificity N
(%)
95%
Confidence
Interval
Sensitivity N
(%)
Specificity N
(%)
95%
Confidence
Interval
VL (97) 93 (95.87) NA 89.78–98.87 95 (97.94) NA 92.75–99.75 97 (100) NA 96.26–100
PKDL (14) 14 (100) NA 95.20–100 14 (100) NA 95.20–100 14 (100) NA 95.20–100
NEHC (25) NA 25 (100) 86.28–100 NA 25 (100) 86.28–100 NA 25 (100) 86.28–100
EHC (25) NA 25 (100) 86.28–100 NA 25 (100) 86.28–100 NA 25 (100) 86.28–100
OD (25) NA 23 (92) 73.97–99.02 NA 25 (100) 86.28–100 NA 25 (100) 86.28–100
Total
Controls
(75)
- 73 (97.33) 90.70–99.68 - 75 (100) 95.2–100 - 75 (100) 95.2–100
Comparative performances of urine-ELISA and Urine dipstick test with serum rK39 rapid diagnostic test
VL, visceral leishmaniasis
PKDL, post kala-azar dermal leishmaniasis
NEHC, non-endemic healthy controls
EHC, endemic healthy controls
OD, other diseases than VL
NA, not applicable.
doi:10.1371/journal.pntd.0005035.t001
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titre in ELISA after 180 days of treatment. Moreover, results of dipsticks tests which were posi-
tive before treatment turned completely negative (16/18) within six months of treatment. Posi-
tivity in two samples even after six months might be an indication of relapse in future and
needs to be monitored for disease. Our results demonstrating the prognostic use of urine-based
ELISA and dipstick assay warrant further detailed longitudinal studies.
Collection, storage and handling of urine samples are safe, noninvasive and advantageous
over serum samples. The advantage of this is particularly to infants with Leishmania infection,
from whom the collection of blood is difficult. Although, dried blood spot on filter paper has
been proven successful in diagnosis and epidemiological studies of VL using DAT, however,
DAT requires central laboratory facility [6,45]. Regarding urine dipstick test, it is a ready-to-
use device which is stored at room temperature and can be used for at least one year with sim-
ple desiccation. It is also easier in handling and does not involve much expertise or sophisti-
cated instruments, thus suitable for outreach diagnosis. The assay does not require
pretreatment of the urine samples as in KAtex test. Urine samples were tested and found stable
and reproducible up to more than six years when stored with 0.1% azide at 4°C [24].
This study, however, has limitations. The VL subjects chosen for the studies were clinically
confirmed thus cannot give an idea about infection versus disease. Population-based study will
be required to evaluate the performance of dipstick test with VL suspected individuals and
asymptomatic carriers in definedVL endemic areas. Moreover, to compare treatment response,
blood samples could not be collected from follow-up patients who came in the hospital outpa-
tient department for routine checkup after at least 6 months of treatment. However, previous
reports suggest persistence of anti-Leishmania antibodies up to six months of VL treatment
[43,44]. This dipstick is currently based on enzyme-catalysed colorimetric reaction which takes
Fig 7. Representative image of dipstick immunochromatographic test. Dipstick assay shows positive results with
double band at the test and control lines and negative results with bands only at the control line.
doi:10.1371/journal.pntd.0005035.g007
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90 min to complete (S8 Fig). It could be reduced to 5 min with the existing gold-tagged lateral
flow technology (already started).
Our findings highlight the potentials of urine-basedELISA and dipstick tests that can offer
an efficient and convenient alternative to invasive diagnostics of VL as well as PKDL. Dipstick
may help to overcome the need for invasive tissue aspiration particularly in primary health
care centres where it is unlikely to be feasible.
Like in the Indian subcontinent, use of rK39-RDT with strict clinical case definition has
marked a good impact in screeningVL cases at the primary level. In East African regions
where performance of rK39-RDT is not good this urine-baseddipstick could be valuable in VL
diagnosis at field settings. Moreover, dipstick test can also suggest the treatment response thus
can be used as a test of cure. The collection of urine is comparatively easier and painless than
withdrawing blood so it can help to screen Leishmania exposure at remote areas. Subsequently
it can contribute in the control programs for VL management and eradication.
Supporting Information
S1 Fig. Antibody capture ELISAwith different dilutions of urine.Comparative optical den-
sity values of LAg-specific IgG antibodies of 5 VL patients, 2 healthy controls, 4 other diseases
(2 malaria and 2 viral fevers) with different dilutions of urine reacted with 1.0 μg/well of LAg.
Urine at 1:10 dilutions shows significant reactivity with VL while HC and OD samples have
less reactivity.
(TIF)
S2 Fig. Antibody-capture ELISA at different concentrations of LAg.Comparative optical
density values of five VL patients (VL 1–5), two healthy controls (C1 and C2), two malaria (M1
and M2) and two viral fevers (V1 and V2) in 1:10 dilution of urine with different concentra-
tions of LAg per well. LAg at 1.5μg/well shows clear difference in antibodies titre betweenVL
with controls.
(TIF)
S3 Fig. Dot blot assay at different concentrations of LAg.The sensitivity and specificity of
LAg at different concentrations (2.0, 1.5, 1.0, and 0.5 μg/dot) tested by dot blot using urine
samples. Strips 1 and 2 represent VL, strip 3 malaria, strip 4 viral fever, and strip 5 and 6
endemic and non-endemic healthy control urine samples, respectively. LAg at 1.5μg/well
depicts visually clear difference betweenVL and controls.
(TIF)
S4 Fig. Dot blot assay with different dilutions of urine. Results of dot blot with undiluted
urine (1:0) and dilutions, 1:2, 1:5, 1:10, and 1:50. Strips 1 and 2 symbolize VL, strip 3 malaria,
strip 4 viral fever, and strip 5 and 6 endemic and non-endemic healthy control urine samples,
respectively. Urine at 1:5 dilutions best distinguishes VL from controls.
(TIF)
S5 Fig. Dot blot assay with different blocking solutions.Dot blot reactivity when the mem-
branes were blocked with 0.1% Tween-20, 1.5%, 3% and 5% BSA and 5% skimmedmilk. In all
the sets, strips 1 and 2 determine VL, strip 3 malaria, strip 4 viral fever, and strip 5 and 6
endemic and non-endemic healthy controls, respectively. Blocking with 5% BSA is optimal for
clear reactivity of VL samples without any cross reactivity in controls.
(TIF)
S6 Fig. Dot blot assay with anti-human IgG as control test. Results of dot blot coated with
different dilutions of rabbit anti-human IgG antibody. In all the sets, strip 1 and 2 determines
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VL urine, strip 3 malaria urine, strip 4 viral fever urine, and strip 5 and 6 are endemic and non-
endemic healthy controls urine, respectively. Antibodies at 1:20 dilutions show equal reactivity
with all urine samples.
(TIF)
S7 Fig. Prototype of a dipstick model. In a typical dipstick model; 1, support zone; 2, sample
contact zone; 3, LAg; 4, test line; 5, anti-human IgG and 6, control line.
(TIF)
S8 Fig. Immunological reactions for positive and negative urine sample in dipsticks.
(TIF)
S1 Table. Reactivity of pre and post treatment VL urine samples in urine based ELISA and
dipstick assay.
(DOCX)
S1 File. Flow diagramof study subjects.
(DOCX)
S2 File. Clinical characteristicsof participants.
(DOCX)
S3 File. STARD Checklist.
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